Decoding the Combinatorial Epigenetic Information of the Mammalian Genome with Engineered DNA Duplex Readers
Developing and commercializing user-friendly kits for mapping novel CpG duplex modifications to enhance epigenetics research and cancer biomarker discovery.
Projectdetails
Introduction
In mammalian genomes, epigenetic modifications of the nucleobase cytosine occur in both strands of the DNA duplex in the sequence “CpG”, and they are central regulators of gene expression as well as important cancer biomarkers.
Current Challenges
However, current analytical techniques cannot reveal the combination in which these modifications occur in the two strands of a DNA duplex. The resulting inability to create genomic maps of these “CpG duplex modifications” represents a major roadblock for future developments in epigenetics research and cancer diagnosis.
Project Overview
We have engineered the first affinity enrichment probes for selectively analyzing novel CpG duplex modifications, and integrated them into user-friendly and cost-effective kits for genomic mapping.
Goals
In this project, we will develop and commercialize two kits for mapping the most important novel CpG duplex modifications consisting of:
- 5-methylcytosine
- 5-hydroxymethylcytosine
These kits will target the epigenetics research and liquid biopsy markets.
Impact
This will provide decisive new impulses for epigenetics research as well as for cancer biomarker discovery and liquid biopsy, both large and rapidly growing markets.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-11-2022 |
Einddatum | 30-4-2024 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- TECHNISCHE UNIVERSITAT DORTMUNDpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Targeted Microarrays for 5-hydroxymethylcytosine-based Diagnosis of Hematological MalignanciesThis project aims to develop a cost-effective DNA chip for mapping 5-hydroxymethylcytosine (5hmC) to identify cancer biomarkers and improve diagnostic testing accessibility. | ERC Proof of... | € 150.000 | 2022 | Details |
Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and DiagnosisEpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors. | ERC Starting... | € 1.500.000 | 2024 | Details |
Towards early cancer detection and tumor classification using epigenomic biomarkers in bloodEpiCblood aims to enhance early cancer detection by increasing cancer-specific cf-nucleosomes through innovative histone modification profiling and computational analysis for improved liquid biopsy assays. | ERC Starting... | € 1.499.999 | 2024 | Details |
Deep multiplexed epigenetic profiling of plasma cell-free nucleosomes for early cancer diagnosticsThis project aims to develop ultra-sensitive methods for detecting histone post-translational modifications in blood plasma to enhance cancer diagnostics and enable universal screening. | ERC Proof of... | € 150.000 | 2024 | Details |
Detecting epigenetic biomarkers in the blood for non-invasive precision oncologyDevelop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution. | ERC Starting... | € 1.500.000 | 2022 | Details |
Targeted Microarrays for 5-hydroxymethylcytosine-based Diagnosis of Hematological Malignancies
This project aims to develop a cost-effective DNA chip for mapping 5-hydroxymethylcytosine (5hmC) to identify cancer biomarkers and improve diagnostic testing accessibility.
Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and Diagnosis
EpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors.
Towards early cancer detection and tumor classification using epigenomic biomarkers in blood
EpiCblood aims to enhance early cancer detection by increasing cancer-specific cf-nucleosomes through innovative histone modification profiling and computational analysis for improved liquid biopsy assays.
Deep multiplexed epigenetic profiling of plasma cell-free nucleosomes for early cancer diagnostics
This project aims to develop ultra-sensitive methods for detecting histone post-translational modifications in blood plasma to enhance cancer diagnostics and enable universal screening.
Detecting epigenetic biomarkers in the blood for non-invasive precision oncology
Develop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution.